IP Library › Granted Patent US 11,510,998
Granted Patent B2
US 11,510,998 · App. 16/061,091 · Granted Nov 29, 2022

Gene therapy for combined methylmalonic acidemia/aciduria and hyperhomocysteinemia/homocystinuria, cobalamin C type, and deficiency of MMACHC

Inventors: Charles P. Venditti (Potomac, MD); Jennifer L. Sloan (Silver Spring, MD)
Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
A61K48/0066A61K47/26A61P43/00C07K14/435C12N15/67C12N15/85C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,510,998
App. No.
16/061,091
Granted
Nov 29, 2022
Kind
B2
Abstract

The present invention provides a synthetic MMACHC polynucleotide comprising a polynucleotide encoding MMACHC that is codon-optimized for expression in a human. Also provided is a polypeptide encoded by a synthetic MMACHC polynucleotide, an expression vector comprising a MMACHC gene sequence under the control of a chicken beta actin (CBA) promoter, and an expression vector comprising a synthetic MMACHC polynucleotide. Methods of treating cobalamin C deficiency and for detecting or tracking exogenous MMACHC are also provided.

Claims (14)

1. A synthetic methylmalonic aciduria cblC type and homocystinuria type C protein (MMACHC) polynucleotide comprising a polynucleotide encoding MMACHC that is codon-optimized for expression in a human, wherein the polynucleotide encoding MMACHC comprises the sequence of SEQ ID NO: 2.

2. The synthetic MMACHC polynucleotide of claim 1 , wherein the polynucleotide further comprises a polynucleotide encoding at least one of a hemagglutinin tag and a 3×FLAG tag.

3. A composition comprising the synthetic MMACHC polynucleotide of claim 1 and a pharmaceutically acceptable carrier.

4. An expression vector comprising the synthetic MMACHC polynucleotide of claim 1 .

5. The expression vector of claim 4 , wherein the synthetic MMACHC polynucleotide is under the control of a chicken beta actin (CBA) promoter.

6. The expression vector of claim 4 , wherein the expression vector is a viral vector.

7. The expression vector of claim 6 , wherein the viral vector is an adeno-associated viral (AAV) vector.

8. The expression vector of claim 7 , wherein the AAV is pseudotyped with at least one of rh10, type 9, type 8, and 7m8 capsid.

9. The expression vector comprising an isolated nucleic acid sequence selected from the group consisting of the nucleotide of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:9.

10. The expression vector of claim 9 , wherein the expression vector comprises the nucleic acid sequence of SEQ ID NO: 5.

11. The expression vector of claim 9 , wherein the expression vector comprises the nucleic acid sequence of SEQ ID NO: 6.

12. The expression vector of claim 9 , wherein the expression vector comprises the nucleic acid sequence of SEQ ID NO: 7.

13. The expression vector of claim 9 , wherein the expression vector comprises the nucleic acid sequence of SEQ ID NO: 8.

14. The expression vector of claim 9 , wherein the expression vector comprises the nucleic acid sequence of SEQ ID NO: 9.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2018
From: VENDITTI, CHARLES P.; SLOAN, JENNIFER L.
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 046771/0583 →
Continuity (3)
Provisional Application 62279285 · Jan 15, 2016
Provisional Application 62266352 · Dec 11, 2015
Related Publication 20180353623A1 · Dec 13, 2018